These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25222742)

  • 21. Assessing the protection of the nanomaterial workforce.
    Schulte PA; Iavicoli I; Rantanen JH; Dahmann D; Iavicoli S; Pipke R; Guseva Canu I; Boccuni F; Ricci M; Polci ML; Sabbioni E; Pietroiusti A; Mantovani E
    Nanotoxicology; 2016 Sep; 10(7):1013-9. PubMed ID: 26865347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Life Cycle of Engineered Nanoparticles.
    González-Gálvez D; Janer G; Vilar G; Vílchez A; Vázquez-Campos S
    Adv Exp Med Biol; 2017; 947():41-69. PubMed ID: 28168665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk assessment of engineered nanomaterials: a survey of industrial approaches.
    Helland A; Scheringer M; Siegrist M; Kastenholz HG; Wiek A; Scholz RW
    Environ Sci Technol; 2008 Jan; 42(2):640-6. PubMed ID: 18284176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered nanomaterials: toward effective safety management in research laboratories.
    Groso A; Petri-Fink A; Rothen-Rutishauser B; Hofmann H; Meyer T
    J Nanobiotechnology; 2016 Mar; 14():21. PubMed ID: 26979818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling approaches for characterizing and evaluating environmental exposure to engineered nanomaterials in support of risk-based decision making.
    Hendren CO; Lowry M; Grieger KD; Money ES; Johnston JM; Wiesner MR; Beaulieu SM
    Environ Sci Technol; 2013 Feb; 47(3):1190-205. PubMed ID: 23293982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards a more effective and efficient governance and regulation of nanomaterials.
    Teunenbroek TV; Baker J; Dijkzeul A
    Part Fibre Toxicol; 2017 Dec; 14(1):54. PubMed ID: 29258600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.
    Som C; Nowack B; Krug HF; Wick P
    Acc Chem Res; 2013 Mar; 46(3):863-72. PubMed ID: 23110540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?
    Hoet P; Legiest B; Geys J; Nemery B
    Drug Saf; 2009; 32(8):625-36. PubMed ID: 19591528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanomaterials in the environment: from materials to high-throughput screening to organisms.
    Thomas CR; George S; Horst AM; Ji Z; Miller RJ; Peralta-Videa JR; Xia T; Pokhrel S; Mädler L; Gardea-Torresdey JL; Holden PA; Keller AA; Lenihan HS; Nel AE; Zink JI
    ACS Nano; 2011 Jan; 5(1):13-20. PubMed ID: 21261306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotoxicology and nanomedicine: making hard decisions.
    Linkov I; Satterstrom FK; Corey LM
    Nanomedicine; 2008 Jun; 4(2):167-71. PubMed ID: 18329962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Health risks of engineered nanomaterials and nanotechnologies].
    Savolainen K; Vainio H
    Duodecim; 2011; 127(11):1097-104. PubMed ID: 21755801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomaterial health effects--part 1: background and current knowledge.
    Powell MC; Kanarek MS
    WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vulnerability and social justice as factors in emergent U.S. nanotechnology risk perceptions.
    Conti J; Satterfield T; Harthorn BH
    Risk Anal; 2011 Nov; 31(11):1734-48. PubMed ID: 21453374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An integrated science-based methodology to assess potential risks and implications of engineered nanomaterials.
    Tolaymat T; El Badawy A; Sequeira R; Genaidy A
    J Hazard Mater; 2015 Nov; 298():270-81. PubMed ID: 26079368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nano-food packaging: an overview of market, migration research, and safety regulations.
    Bumbudsanpharoke N; Ko S
    J Food Sci; 2015 May; 80(5):R910-23. PubMed ID: 25881665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of engineered nanomaterials: current challenges, insights and future directions.
    Lai RWS; Yeung KWY; Yung MMN; Djurišić AB; Giesy JP; Leung KMY
    Environ Sci Pollut Res Int; 2018 Feb; 25(4):3060-3077. PubMed ID: 28639026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of nanomaterials in dentistry: covariates of risk and benefit perceptions among dentists and dental hygienists in Norway.
    Xenaki V; Costea DE; Marthinussen MC; Cimpan MR; Åstrøm AN
    Acta Odontol Scand; 2020 Mar; 78(2):152-160. PubMed ID: 31561718
    [No Abstract]   [Full Text] [Related]  

  • 40. Material-specific properties applied to an environmental risk assessment of engineered nanomaterials - implications on grouping and read-across concepts.
    Wigger H; Nowack B
    Nanotoxicology; 2019 Jun; 13(5):623-643. PubMed ID: 30727799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.